AstraZeneca suspends share buyback
A pharmacist counts pills in a pharmacy.
AstraZeneca Plc said on Monday it suspended its share repurchase programme with immediate effect.
The British drugmaker, however, maintained its core earnings target for the full year at between $6 and $6.30 per share.
“As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the board and I complete the company's ongoing annual strategy update,” said Pascal Soriot, who was recently appointed as CEO. - Reuters